
Kodiak Sciences Reports Positive Phase 3 Results for Zenkuda and KSI-501
Kodiak Sciences announced that its pivotal DAYBREAK trial met primary endpoints for both Zenkuda and tabirafusp-ted, demonstrating vision gains and retinal drying in patients with wet age-related macular degeneration. The results show that Zenkuda maintains non-inferiority to aflibercept while offering extended durability for a majority of patients.






















